Today, Humana Inc. (HUM) Price Target Cut to $217.00

Today, Humana Inc. (HUM) Price Target Cut to $217.00

Humana Inc. (NYSE:HUM) had its target price dropped by analysts at Royal Bank Of Canada from $222.00 to $217.00 in a note issued to investors on Thursday. The brokerage currently has a “sector perform” rating on the insurance provider’s stock. Royal Bank Of Canada’s target price would indicate a potential upside of 27.03% from the stock’s previous close.

HUM has been the topic of several other reports. Zacks Investment Research lowered Humana from a “buy” rating to a “hold” rating in a research note on Wednesday, September 21st. JPMorgan Chase & Co. downgraded Humana from an “overweight” rating to a “neutral” rating and dropped their target price for the company from $196.00 to $150.00 in a report on Friday, July 8th. Evercore ISI began coverage on Humana in a report on Thursday, September 22nd. They set a “buy” rating and a $200.00 target price on the stock. Argus reiterated a “hold” rating on shares of Humana in a report on Tuesday, August 23rd. Finally, Wolfe Research upgraded Humana to an “outperform” rating and set a $192.00 target price on the stock in a report on Thursday, July 21st. Seven equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $200.50.

Humana (NYSE:HUM) opened at 170.82 on Thursday. Humana has a one year low of $150.00 and a one year high of $191.65. The company has a 50-day moving average price of $175.94 and a 200-day moving average price of $175.74. The firm has a market capitalization of $25.46 billion, a P/E ratio of 26.24 and a beta of 0.90.

Humana (NYSE:HUM) last released its quarterly earnings data on Wednesday, August 3rd. The insurance provider reported $2.30 earnings per share for the quarter, beating the consensus estimate of $2.23 by $0.07. The business had revenue of $14 billion for the quarter, compared to analyst estimates of $13.59 billion. Humana had a return on equity of 11.11% and a net margin of 1.76%. The company’s revenue was up 2.0% compared to the same quarter last year. During the same period in the previous year, the company posted $1.67 EPS. On average, equities research analysts anticipate that Humana will post $9.24 EPS for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 28th. Investors of record on Thursday, October 13th will be given a dividend of $0.29 per share. The ex-dividend date is Tuesday, October 11th. This represents a $1.16 dividend on an annualized basis and a yield of 0.68%. Humana’s dividend payout ratio is currently 18.18%.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in HUM. RidgeWorth Capital Management LLC bought a new position in Humana during the second quarter worth about $75,609,000. FMR LLC raised its position in shares of Humana by 21.5% in the second quarter. FMR LLC now owns 1,876,497 shares of the insurance provider’s stock worth $337,544,000 after buying an additional 331,537 shares during the period. Renaissance Technologies LLC raised its position in shares of Humana by 246.3% in the first quarter. Renaissance Technologies LLC now owns 446,000 shares of the insurance provider’s stock worth $81,596,000 after buying an additional 317,200 shares during the period. Adage Capital Partners GP L.L.C. raised its position in shares of Humana by 39.4% in the first quarter. Adage Capital Partners GP L.L.C. now owns 940,360 shares of the insurance provider’s stock worth $172,039,000 after buying an additional 265,700 shares during the period. Finally, BlackRock Investment Management LLC raised its position in shares of Humana by 34.3% in the second quarter. BlackRock Investment Management LLC now owns 950,666 shares of the insurance provider’s stock worth $171,006,000 after buying an additional 242,769 shares during the period. Institutional investors and hedge funds own 93.27% of the company’s stock.

About Humana

Related posts

Leave a Comment